From: Flotillin-2 is associated with breast cancer progression and poor survival outcomes
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
No. patients | p | Regression coefficient (SE) | p | Relative risk | 95% confidence interval | |
FLOT2 | 0.002 | |||||
Low expression | 89 | <0.001 | 1.209(0.172) | Ref | ||
High expression | 82 | 0.002 | 4.492 | 1.740-11.598 | ||
Clinical stage | <0.001 | |||||
I | 21 | Ref | ||||
II | 92 | <0.001 | 1.618(0.314) | 0.824 | 1.190 | 0.256-5.522 |
III | 46 | 0.329 | 2.236 | 0.444-11.264 | ||
IV | 12 | 0.014 | 8.594 | 1.545-47.790 | ||
ErbB-2 | 0.06 | |||||
0 | 42 | Ref | ||||
1 | 52 | <0.001 | 0.376(0.106) | 0.272 | 0.602 | 0.244-1.489 |
2 | 38 | 0.237 | 1.625 | 0.727-3.629 | ||
3 | 30 | 0.164 | 1.811 | 0.785-4.178 | ||
4 | 9 | 0.253 | 2.005 | 0.608-6.609 | ||
Histological differentiation | 0.005 | |||||
Well | 9 | <0.001 | 1.283(0.262) | Ref | ||
Moderate | 113 | 0.783 | 0.810 | 0.181-3.631 | ||
Poor | 49 | 0.327 | 2.105 | 0.475-9.330 |